The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1 in combination with an immunotherapy.

The present disclosure concerns methods of treating cancer with neoantigenic peptides such that durable clinical benefits are obtained, and compositions and methods for determining whether DCB can be predicted or assessed for a patient to be treated with a therapeutic comprising neoantigen.

The present disclosure relates to methods that involve obtaining a tissue or liquid biopsy sample from a subject. Extracellular vesicles and particles are separated from the sample, and protein from the separated extracellular vesicles and particles is isolated to form an extracellular vesicle and particle protein sample. The extracellular vesicle and particle protein sample is subjected to a detection assay suitable for detecting the sample's protein signature, and the presence, absence, status, and/or type of cancer in the subject is identified based the detected protein signature.

The present disclosure relates to a method of isolating extracellular vesicles directly from human tissues. The invention further relates to a method of identifying disease and tissue specific membrane proteins on extracellular vesicles by membrane isolation and proteomic analysis. The invention further relates to methods of diagnosing diseases by capturing extracellular vesicles by the use of disease specific membrane proteins from body fluids, and detecting or analyzing molecular signatures (proteome, DNA, and RNA) on captured extracellular vesicles. Moreover, the present invention relates to kits, apparatus and software required for implementing aforementioned methods.

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.

The invention provides methods and devices for determining molecular signatures in a cancer that predict response to a MARPK pathway inhibitor and methods of use of such signatures.

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, prognosis, risk, and response to treatment.

The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

The present disclosure provides methods for modulating (e.g., preventing, inhibiting, blocking) the interaction of PSGL-1 and VISTA with agents (e.g., antibodies) that bind to PSGL-1 and/or VISTA.